Fox Jonathan C
CIK: 0001655016
Fox Jonathan C's purchase track record
Fox Jonathan C has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/11/2025 | EWTX | $199K | +44.3% | +58.3% | +8.1% |
| 12/26/2023 | EWTX | $101K | +80.0% | +82.7% | +14.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| EWTX | ▲ Buy | Grant | 308 | $0 | 10/1/2026 | View on chart |
| EWTX | ▲ Buy | Grant | 319 | $0 | 7/1/2026 | View on chart |
| EWTX | ▲ Buy | Grant | 339 | $0 | 4/1/2026 | View on chart |
| EWTX | ▲ Buy | Grant | 473 | $0 | 1/2/2026 | View on chart |
| EWTX | ▲ Buy | Open Market | 10,700 | $199K | 11/11/2025 | View on chart |
| EWTX | ▲ Buy | Grant | 728 | $0 | 10/1/2025 | View on chart |
| EWTX | ▲ Buy | Grant | 858 | $0 | 7/1/2025 | View on chart |
| EWTX | ▲ Buy | Grant | 559 | $0 | 4/1/2025 | View on chart |
| EWTX | ▲ Buy | Open Market | 10,857 | $101K | 12/26/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Edgewise Therapeutics Doses First Patient in Phase 2 Trial
Edgewise Therapeutics has dosed the first participant in its Phase 2 EQUINOX-HFpEF trial for EDG-15400, a drug intended to treat heart failure with preserved ejection fraction. This marks a key clinical milestone for the company. The stock is currently trading near its 52-week high, with analysts maintaining an average price target of $52.62.
Edgewise Therapeutics Doses First Patient in Phase 2 Trial. Edgewise Therapeutics has dosed the first participant in its Phase 2 EQUINOX-HFpEF trial for EDG-15400, a drug intended to treat heart failure with preserved ejection fraction. This marks a key clinical milestone for the company. The stock is currently trading near its 52-week high, with analysts maintaining an average price target of $52.62.